Liquidia (NASDAQ:LQDA) Insider Sells $252,418.24 in Stock

Liquidia Corporation (NASDAQ:LQDA) insider Scott Moomaw sold 8,863 shares of Liquidia stock in a transaction dated Monday, October 12th. The stock was sold at an average price of $28.48, for a total transaction of $252,418.24. Following the completion of the sale, the insider directly owned 181,487 shares in the company, valued at approximately $5,168,749.76. This represents a 4.66% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Liquidia Stock Up 2.5%

LQDA opened at $34.78 on Friday. The company has a quick ratio of 2.12, a current ratio of 2.31 and a debt-to-equity ratio of 0.63. The stock has a market cap of $3.11 billion, a price-to-earnings ratio of 24.77 and a beta of 0.61. Liquidia Corporation has a twelve month low of $21.94 and a twelve month high of $93.61. The company’s 50-day moving average price is $61.21 and its two-hundred day moving average price is $61.73.

Liquidia (NASDAQ:LQDA) last released its earnings results on Wednesday, August 12th. The company reported $0.74 earnings per share for the quarter, missing analysts’ consensus estimates of $0.76 by ($0.02). Liquidia had a net margin of 30.74% and a return on equity of 149.65%. The company had revenue of $171.68 million for the quarter, compared to the consensus estimate of $168.48 million. During the same period in the prior year, the company earned ($0.49) earnings per share. The firm’s revenue was up 1842.1% on a year-over-year basis. As a group, equities analysts expect that Liquidia Corporation will post 2.05 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the company. Raymond James Financial reiterated an “outperform” rating on shares of Liquidia in a research note on Thursday, October 8th. Citigroup reissued a “neutral” rating on shares of Liquidia in a research report on Thursday, October 1st. Wedbush set a $58.00 target price on Liquidia in a research note on Friday, October 2nd. Zacks Research lowered Liquidia from a “hold” rating to a “strong sell” rating in a research note on Tuesday, September 22nd. Finally, Wall Street Zen cut Liquidia from a “buy” rating to a “hold” rating in a research report on Saturday, October 3rd. One investment analyst has rated the stock with a Strong Buy rating, five have given a Buy rating, four have assigned a Hold rating and two have assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus price target of $72.85.

Trending Headlines about Liquidia

Here are the key news stories impacting Liquidia this week:

• Positive Sentiment: Liquidia settled all six patent and antitrust disputes with United Therapeutics for a net $380.7 million, allowing continued commercialization of YUTREPIA for pulmonary arterial hypertension. Ending the litigation removes significant legal uncertainty and avoids a potentially market-disrupting appeal. Liquidia shares surge as settlement ends United Therapeutics litigation
• Positive Sentiment: Analyst sentiment improved after the settlement. LifeSci Capital upgraded LQDA to “outperform” with a $59 price target, while HC Wainwright raised its target to $65 and initiated or reiterated a “buy” rating. BTIG also upgraded the stock to “buy” with a $70 target. LifeSci Capital upgrades Liquidia
• Positive Sentiment: Preliminary third-quarter YUTREPIA net product sales were reported at $222.7 million. Management expects existing cash and ongoing sales to fund the settlement and planned clinical programs without requiring additional financing, supporting the investment case if commercial momentum continues.
• Positive Sentiment: Trading activity reflected renewed speculative interest, with call-option volume more than doubling its typical level. This suggests some traders are positioning for additional gains following the legal resolution.
• Neutral Sentiment: Multiple executives and insiders, including the CEO and CFO, sold shares at $28.48 under pre-arranged Rule 10b5-1 plans to cover tax obligations on vested equity awards. Because the transactions were planned and sellers retained substantial holdings, they are a limited standalone signal of sentiment. Liquidia insider sale filing
• Negative Sentiment: The $380.7 million settlement will require $175 million within 30 business days, $145.4 million in 2027 installments and $60.3 million tied to antitrust litigation. These payments could materially reduce Liquidia’s cash cushion and constrain future investment.
• Negative Sentiment: Liquidia agreed not to appeal the infringement ruling and will remove the PH-ILD indication from YUTREPIA’s label, narrowing the drug’s addressable market. Needham lowered its price target to $58, despite maintaining a “buy” rating, highlighting ongoing execution and valuation risks.

Hedge Funds Weigh In On Liquidia

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. The Manufacturers Life Insurance Company increased its stake in shares of Liquidia by 63.3% in the first quarter. The Manufacturers Life Insurance Company now owns 58,265 shares of the company’s stock worth $2,199,000 after purchasing an additional 22,592 shares in the last quarter. Bank of New York Mellon Corp bought a new stake in shares of Liquidia in the second quarter valued at approximately $29,694,000. Seven Fleet Capital Management LP raised its position in shares of Liquidia by 25.2% in the second quarter. Seven Fleet Capital Management LP now owns 256,603 shares of the company’s stock valued at $20,459,000 after purchasing an additional 51,727 shares during the period. Bank of America Corp DE raised its position in shares of Liquidia by 18.7% in the first quarter. Bank of America Corp DE now owns 2,287,792 shares of the company’s stock valued at $86,341,000 after purchasing an additional 360,372 shares during the period. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Liquidia during the 2nd quarter valued at approximately $1,993,000. Institutional investors own 64.54% of the company’s stock.

About Liquidia

Liquidia Corporation is a biopharmaceutical company focused on developing and commercializing therapies for patients with serious cardiopulmonary diseases and other rare conditions. The company uses its proprietary PRINT technology to engineer drug particles with controlled size, shape and composition, with the goal of improving the delivery and performance of medicines.

Liquidia’s lead product is Yutrepia (treprostinil) inhalation powder, a dry-powder inhaler designed for the treatment of pulmonary arterial hypertension (PAH).